WallStSmart

Boston Scientific Corp (BSX)vsIntelligent Bio Solutions Inc. (INBS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Boston Scientific Corp generates 560423% more annual revenue ($20.07B vs $3.58M). BSX leads profitability with a 14.4% profit margin vs 0.0%. BSX earns a higher WallStSmart Score of 63/100 (C+).

BSX

Buy

63

out of 100

Grade: C+

Growth: 8.0Profit: 6.5Value: 8.7Quality: 5.5
Piotroski: 4/9

INBS

Hold

40

out of 100

Grade: D

Growth: 6.3Profit: 2.5Value: 5.0Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BSXUndervalued (+1.2%)

Margin of Safety

+1.2%

Fair Value

$70.62

Current Price

$69.78

$0.84 discount

UndervaluedFair: $70.62Overvalued

Intrinsic value data unavailable for INBS.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BSX4 strengths · Avg: 8.3/10
Market CapQuality
$101.28B9/10

Large-cap with strong market position

PEG RatioValuation
0.758/10

Growing faster than its price suggests

Revenue GrowthGrowth
15.9%8/10

15.9% revenue growth

Free Cash FlowQuality
$1.01B8/10

Generating 1.0B in free cash flow

INBS2 strengths · Avg: 10.0/10
Price/BookValuation
0.4x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
47.6%10/10

Revenue surging 47.6% year-over-year

Areas to Watch

BSX1 concerns · Avg: 4.0/10
P/E RatioValuation
35.1x4/10

Premium valuation, high expectations priced in

INBS4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$5.50M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Return on EquityProfitability
-1.5%2/10

ROE of -1.5% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : BSX

The strongest argument for BSX centers on Market Cap, PEG Ratio, Revenue Growth. Revenue growth of 15.9% demonstrates continued momentum. PEG of 0.75 suggests the stock is reasonably priced for its growth.

Bull Case : INBS

The strongest argument for INBS centers on Price/Book, Revenue Growth. Revenue growth of 47.6% demonstrates continued momentum.

Bear Case : BSX

The primary concerns for BSX are P/E Ratio.

Bear Case : INBS

The primary concerns for INBS are EPS Growth, Market Cap, Profit Margin.

Key Dynamics to Monitor

BSX profiles as a growth stock while INBS is a hypergrowth play — different risk/reward profiles.

INBS carries more volatility with a beta of 4.63 — expect wider price swings.

INBS is growing revenue faster at 47.6% — sustainability is the question.

BSX generates stronger free cash flow (1.0B), providing more financial flexibility.

Bottom Line

BSX scores higher overall (63/100 vs 40/100) and 15.9% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Boston Scientific Corp

HEALTHCARE · MEDICAL DEVICES · USA

Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.

Intelligent Bio Solutions Inc.

HEALTHCARE · MEDICAL DEVICES · USA

Intelligent Bio Solutions Inc. (INBS) is a forward-thinking biotechnology company committed to revolutionizing healthcare through the development of innovative diagnostic solutions and biomarker-driven technologies, especially in the realm of drug abuse testing and monitoring. Leveraging cutting-edge scientific advancements, the company aims to enhance healthcare outcomes by offering highly accurate and rapid-testing methodologies that facilitate timely clinical decision-making. Positioned strategically at the nexus of technology and healthcare, INBS is well-positioned to capitalize on the growing demand for advanced diagnostic tools in a dynamic market landscape.

Want to dig deeper into these stocks?